No Data
Jet Biotech: Third quarter report 2024
Third Quarter Report 2024
Guangzhou Jet Bio-Filtration (688026.SH) released its performance for the first three quarters, with a net income of 50.16 million yuan, a year-on-year increase of 259.26%.
guangzhou jet bio-filtration (688026.SH) disclosed the third quarter report for 2024, during the reporting period, the company achieved revenue of 3.9...
guangzhou jet bio-filtration (688026.SH): net income of 50.1568 million yuan in the first three quarters, a year-on-year increase of 259.26%
Guangzhou Jet Bio-filtration (688026.SH) announced on October 23 that the company's revenue for the first three quarters was 0.391 billion yuan, an 18.56% year-on-year increase; net income attributable to shareholders of the listed company was 50.1568 million yuan, a 259.26% year-on-year increase; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 44.0412 million yuan, a 330.98% year-on-year increase; basic earnings per share was 0.41 yuan.
guangzhou jet bio-filtration (688026.SH): has launched IVF-specific cell culture dishes, currently in the market promotion stage
Guangzhou Jet Bio-filtration (688026.SH) announced on October 22 that the company has launched IVF-specific cell culture dishes on the investor interaction platform, which are currently in the market promotion stage. The company will continue to expand the IVF product line in the future, with multiple related products currently under development.
Guangzhou Jet Bio-Filtration (688026.SH): bank account 11.4731 million yuan frozen.
On October 14th, Gelonghui announced that part of the funds in the company's account, amounting to 11.4731 million yuan, have been frozen by the court. The freezing of funds in the bank account is related to a contract dispute between the company and Hesheng Medical Mould Procurement. Hesheng Medical applied to the Huangpu District People's Court of Guangzhou for property preservation measures. As of the date of this announcement, the case is still pending review and has not yet been heard in court.
Guangzhou Jet Bio-Filtration Co., Ltd. (SHSE:688026) Might Not Be As Mispriced As It Looks After Plunging 29%
No Data
